Lamotrigine is under clinical development by Azurity Pharmaceuticals and currently in Pre-Registration for Partial Seizure. According to GlobalData, Pre-Registration drugs for Partial Seizure have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Lamotrigine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lamotrigine (AUC-025, ET-105) is under development for the treatment of partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome. It is a liquid formulation administered through oral route. It acts by targeting voltage-sensitive sodium channels.
Azurity Pharmaceuticals overview
Azurity Pharmaceuticals, a subsidiary of NovaQuest Capital Management LLC, is a pharmaceutical company that develops and distributes pharmacy kits. The company offers products such as oral suspensions, suppositories, oral solutions, and topical. Its oral solutions and oral suspensions include mouthwashes, anti-microbial and PPIs; and topicals comprise hydrocortisone and testosterone; and suppositories include progesterone VGS. Azurity Pharmaceuticals also provides facilities for distribution, warehousing, and manufacturing operations and management. The company serves hospital and long term care pharmacies, pharmacy chains, and independent pharmacies. It provides prescription compounding kits for physicians, patients, pharmacists, and managed care providers. Azurity Pharmaceuticals is headquartered in Woburn, Massachusetts, the US.
For a complete picture of Lamotrigine’s drug-specific PTSR and LoA scores, buy the report here.